Semaglutide for Weight Loss: Wegovy Injections and Tablets
Semaglutide is a GLP-1 receptor agonist used in specific FDA-approved products for weight management and other indications. W8MD helps eligible patients compare formulation, dose, coverage, tolerability and alternatives.
What patients should know
Wegovy formulations contain semaglutide and are used with reduced-calorie nutrition and increased physical activity. Current FDA labeling includes weekly injection and daily tablet formulations for eligible adults; injection labeling also includes specific pediatric and cardiovascular-risk indications. Product selection and dosing must follow the current prescribing information.
Semaglutide can reduce appetite and energy intake, but benefit is not guaranteed. A gradual escalation schedule is used to improve tolerability. Stopping treatment may be followed by weight regain, making maintenance planning important.
Who may be evaluated
- Eligible adults with obesity or qualifying overweight and a related condition
- Patients interested in weekly injection or an approved oral formulation
- People able to follow administration and escalation instructions
- Patients whose history does not include product-specific contraindications
Potential advantages
- Evidence-based chronic weight-management option
- Multiple formulation choices under current labeling
- Appetite and fullness support
- Integration with nutrition, sleep and maintenance care
At-a-glance comparison
| Formulation | Schedule | Key point |
|---|---|---|
| Wegovy injection | Once weekly | Preset-dose pens with product-specific escalation |
| Wegovy tablet | Once daily | Specific fasting and administration directions must be followed |
| Wegovy HD | Once weekly | 7.2 mg higher-dose adult option approved in 2026 |
Safety and medical supervision
- Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 and after serious hypersensitivity to semaglutide.
- Important risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions and other label-specific warnings.
- People with diabetes may need monitoring for hypoglycemia when used with insulin or insulin secretagogues and for diabetic retinopathy complications.
- Do not combine with other semaglutide-containing products or other GLP-1 receptor agonists.
This summary cannot replace the current FDA-approved prescribing information or an individualized medical evaluation. Tell the clinician about every prescription, over-the-counter medicine, supplement, allergy, pregnancy plan and relevant medical condition.
How W8MD can help
Personalized evaluation
W8MD reviews weight history, prior attempts, conditions, medicines, contraindications, sleep, nutrition, goals, insurance and cost.
Follow-up and maintenance
Care may include response monitoring, adverse-effect management, dose planning, nutrition, lean-mass goals, sleep-apnea evaluation and long-term maintenance.
Brooklyn / NYC: 2632 East 21st Street, Suite L3, Brooklyn, NY 11235 · 718-946-5500
Northeast Philadelphia: 1718 Welsh Road, 2nd Floor, Suite C, Philadelphia, PA 19115 · 215-676-2334
Medical evaluation is required. Eligibility, prescription, availability, coverage, price, response and adverse effects vary.
Related W8MD resources
Prescription hub · Medication guide · GLP-1 comparison · Tirzepatide · Phentermine · Insurance · Medical weight loss · W8MD.com medication guides · NYC medical weight loss · Philadelphia medical weight loss · Anti-obesity medication encyclopedia
Frequently asked questions
Is semaglutide the same as Ozempic?
Semaglutide is the ingredient, but Ozempic and Wegovy are distinct products with different approved indications and dosing.
How quickly is the dose increased?
The schedule depends on the formulation and tolerability. Follow the current label and prescriber instructions rather than accelerating the dose.
What if nausea occurs?
Smaller meals, avoiding heavy foods and hydration may help, but persistent vomiting, severe abdominal pain or dehydration requires prompt clinical advice.
Authoritative references
References are provided for education. Product labeling changes; clinicians and patients should consult the current FDA-approved label.
Request a W8MD callback
For appointments and time-sensitive questions, call Brooklyn at 718-946-5500 or Philadelphia at 215-676-2334. Do not submit urgent, confidential medical, insurance, financial or identifying information through this general form.
You must be logged in to post a comment.